Live Breaking News & Updates on Cataract refract

Stay informed with the latest breaking news from Cataract refract on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Cataract refract and stay connected to the pulse of your community

BLOG: Will cataract surgery improve your patient's sleep?

Blogs | | Our exposure to light powerfully regulates the daily cycle of alertness, relaxation and sleep.

Tualatin , Oregon , United-states , Heather-biele , Oliver-kuhn-wilken , Tosinig-optom , Byoliver-kuhn-wilken , Laser-institute-tualatin-clinic , Brown-university , Johnson , Ment-health , Pacific-cataract

ZEPTO Intraocular Lens Positioning System Enables Growing Office-Based Cataract Surgery Trend; Provides Precision, Efficiency, and Affordability

/PRNewswire/ -- The nation's leading ophthalmic surgeons find the ZEPTO IOL Positioning System™ from Centricity Vision Inc. improves the precision and...

Gainesville , Florida , United-states , California , Shalesh-kaushal , Rob-thornhill , Clin-ophthalmol , Centricity-vision-inc , Twitter , Facebook , Capwell-communications , Centricity-vision

Centricity Vision Announces Launch of ZEPTO Plus Handpiece for the ZEPTO Intraocular Lens Positioning System

/PRNewswire/ -- Centricity Vision Inc., a global ophthalmic technology company and developer of the ZEPTO IOL Positioning System™, today announced the launch...

California , United-states , Chicago , Illinois , American , Holladayj-sretavan , Rob-thornhill , William-trattler , Clin-ophthalmol , Prnewswire-centricity-vision-inc , Centricity-vision-inc , Twitter

Alcon Completes Availability of Clareon Portfolio with Clareon Toric During AAO 2022

Alcon Completes Availability of Clareon Portfolio with Clareon Toric During AAO 2022
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states , Geneva , Genè , Switzerland , Chicago , Illinois , American , Clareon-monofocal , Skou-thomsen , Daniel-cravens , Clareon-iols , Melanie-mccoy

Novaliq submits New Drug Application seeking approval for first-of-a-kind Dry Eye Disease Treatment CyclASol®

/PRNewswire/ -- Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free...

Cambridge , Cambridgeshire , United-kingdom , Heidelberg , Baden-wüberg , Germany , United-states , Netherlands , Holland , Americans , Christian-roesky , Mathias-hothum

Novaliq submits New Drug Application seeking approval for first-of-a-kind Dry Eye Disease Treatment CyclASol

HEIDELBERG, Germany, and CAMBRIDGE, MA, Aug. 9, 2022 /PRNewswire/ -- Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol water-free technology, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for CyclASol (cyclosporine ophthalmic solution), a proposed novel treatment for the signs and symptoms of dry eye disease (DED). CyclASol has demonstrated in two pivotal studies fast onset of therapeutic effect in the indication, clinical meaningful improvement of ocular surface damage, and excellent tolerability. Results from a 12-month long-term study confirmed that the effects are maintained, and even improved for most sign and symptom endpoints. "This is the first submission of a novel product category of water-free topical drug therapies utilizing EyeSol as a drug carrier", said Christian Roesky, Ph.D., CEO, Novaliq. "CyclASol is a first-of-a-kind drug therapy and aims to expand treatment success for patients with dry eye disease and their eye care professionals. If approved by the FDA, CyclASol addresses important unmet medical needs in DED through its ocular surface healing effect combined with high comfort of administration." Dry eye is one of the most common ocular surface disorders, with approximately 18 million Americans diagnosed with DED.1,2 Inflammation and immunologic processes play a key role in the pathology of the disease. A compromised ocular surface secondary to DED may also compromise refractive measurements before keratorefractive and phacorefractive surgeries and adversely impact expected visual outcomes after these surgeries.3,4 The impact of the corneal surface damage secondary to DED on visual function is an underestimated aspect of the disease. Multiple guidelines recommend treatment of the corneal surface damage prior to ocular procedures. A high unmet need remains for better tolerated drugs with an early onset of therapeutic effect, which are compelling to be used and prescribed.5,6 "We are very proud to see another product rapidly moving to the market, which marks yet another important inflection point and milestone in Novaliq's growth trajectory", said Dr. Mathias Hothum, board member and managing director of dievini. "We are currently evaluating the commercialization strategies which includes talking to interested parties." About CyclASol CyclASol is a first-of-a-kind topical treatment of cyclosporine, a potent anti-inflammatory and selective immunomodulatory drug. Whilst not water-soluble, cyclosporine is soluble in the EyeSol excipient perfluorobutylpentane allowing for its improved bioavailability and better efficacy on the target tissue. The product contains no oils, no surfactants and is preservative-free due to the novel carrier. This provides additional clinical benefits for patients, such as improved tolerability and decreased visual disturbances. The NDA is supported by safety and efficacy results in over 1,000 patients with DED from a Phase 2 dose finding study, the Phase 2b/3 ESSENCE-1 study, the Phase 3 ESSENCE-2 study and its open label extension study.7,8 CyclASol has demonstrated in two independent adequate and well-controlled, multicenter studies (ESSENCE-1 and ESSENCE-2) clinically meaningful and statistically significant improvements in the indication. Effects on the ocular surfaceinclude a statistically significant reduction in total corneal fluorescein staining (tCFS) score favoring CyclASol in both studies at Days 15 and 29. Up to 71.6% of patients responded within four weeks with a clinically meaningful improvement of 3 grades in total corneal staining. This proportion of responders was significantly higher compared to vehicle-treated patients in both studies. Responders showed also statistically significant improvements in a variety of symptoms compared to non-responders at day 29. The ASCRS guidelines recognize corneal staining as the single most important clinical sign of DED as it indicates the level of epithelial damage and visual impairment, and if left undertreated, DED can become chronic and more difficult to treat.3 Effect on tear production: In both studies, compared to vehicle at the end of treatment, there was a statistically significant (p<0.05) higher percentage of patientswith increases of 10 mm from baseline in Schirmer's tear test score at Day 85 and Day 29, respectively, confirming a known effect of the active ingredient cyclosporine. Meeting this endpoint in two independent studies is clinically meaningful on its own and considered to demonstrate efficacy for the treatment of signs and symptoms of DED. Head-to-head dataversus Restasisfrom the phase 2 study suggest that CyclASol has a stronger and faster therapeutic effect on the ocular surface.8 Maintenance of effectresults from the long-term study CYS-005 confirmed that the effect of CyclASol was maintained, and even improved for most endpoints, over the 52-week treatment period. Safety and Tolerability: Tolerability of CyclASol was shown by high drop comfort patient ratings in both studies. The most common adverse reaction observed was instillation site reactions, which was reported in 8.1% of patients in the pooled studies. These were in all but one case mild. The only other adverse reaction reported in > 2% of the patients was visual acuity reduced (2.7%). About Novaliq Novaliq is a biopharmaceutical company focusing on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol, the worldwide first water-free technology. EyeSol is Novaliq's proprietary water-free technology using ultrapure semifluorinated alkanes (SFAs) that are physically, chemically, and physiologically inert with excellent biocompatibility and a very good safety profile. Novaliq offers an industry-leading portfolio addressing today's unmet medical needs of millions of patients with eye diseases. In July 2022 submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) was announced seeking approval for NOV03 (perfluorohexyloctane), for the proposed indication of treating the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD). In addition to CyclASol, the company continues to progress multiple additional pipeline opportunities based on its validated EyeSol platform, both in ophthalmology and adjacent indications like dermatology. Novaliq GmbH is headquartered in Heidelberg, Germany and Novaliq Inc. has an office in Cambridge, MA, USA. The long-term shareholder is dievini Hopp BioTech holding GmbH & Co. KG, an active investor in Life and Health Sciences companies. More on www.novaliq.com. Recommended Readings Leonardi A, Modugno RL, & Salami E. Allergy and Dry Eye Disease. Ocular immunology and inflammation. 2021; 29:1168-1176 2020 Dry Eye Products Market Report: A global Analysis for 2019 to 2025. Market Scope Starr CE, Gupta PK, Farid M, Beckman KA, Chan CC, Yeu E, Gomes JAP, Ayers BD, BerdahlJP, Holland EJ, Kim T, Mah FS(the ASCRSCornea Clinical Committee). An algorithm for the preoperative diagnosis and treatment of ocular surface disorders. JCataract Refract Surg. 2019; 45:669-684 Donaldson K, ParkhurstG, SaenzB, Whitley W, Williamson B, Hovanesian J. Call to action: treating dry eye disease and setting the foundation for successful surgery. JCataract Refract Surg. 2022; 48:623-629 White DE, Zhao Y, OgundeleA, Fulcher N, AcsA, Moore-Schiltz L, KarpeckiPM. Real-World Treatment Patterns Of CyclosporineOphthalmic Emulsion And LifitegrastOphthalmic Solution Among Patients With Dry Eye. Clin Ophthalmol. 2019; 13:2285-2292 Dunn JD, KarpeckiPM, MeskeME, ReissmanD. Evolving knowledge of the unmet needs in dry eye disease. Am J ManagCare. 2021; 27:S23-32 Sheppard JD, WirtaDL, McLaurin E, BoehmerBE, CiolinoCB, MeidesAS, Schlter T, Ousler GW, UsnerD, KrsserS. A Water-free 0.1% CyclosporineA Solution for Treatment of Dry Eye Disease: Results of the Randomized Phase II/III ESSENCE Study. Cornea. 2021; 40:1290-1297 WirtaDL, Torkildsen G

Cambridge , Cambridgeshire , United-kingdom , Heidelberg , Baden-wüberg , Germany , United-states , Netherlands , Holland , Americans , Christian-roesky , Mathias-hothum

Novaliq GmbH: Novaliq submits New Drug Application seeking approval for first-of-a-kind Dry Eye Disease Treatment CyclASol

HEIDELBERG, Germany, and CAMBRIDGE, MA, Aug. 9, 2022 /PRNewswire/ -- Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol

Cambridge , Cambridgeshire , United-kingdom , Heidelberg , Baden-wüberg , Germany , United-states , Netherlands , Holland , Americans , Christian-roesky , Mathias-hothum

CAIRS can be customized for treatment of keratoconus, other corneal ectasia conditions

Ocular Surgery News | The term corneal allogenic intrastromal ring segments, or CAIRS, refers to the intra-channel placement of allogenic tissue for the treatment of corneal ectasia.The allogenic tissue can be from any source, including fresh-cut CAIRS, unprocessed or processed CAIRS, and preserved or packaged CAIRS with or without modifications and with or without storage and shelf-life capabilities. The procedure

Germany , Australia , United-states , India , Israel , Lebanon , South-africa , Ireland , Canada , Chennai , Tamil-nadu , Turkey

New Study Shows Intraocular Lens Centration and Stability May Be Improved When ZEPTO Capsulotomy Platform is Used with Purkinje Reflections

/PRNewswire/ -- Centricity Vision Inc., a global ophthalmic technology company and developer of the ZEPTO® Precision Cataract Surgery Platform, today announced...

California , United-states , Rob-thornhill , David-sretavan , Clin-ophthalmol , Vance-thompson , Jack-holladay , Centricity-vision-inc , Twitter , Facebook , Capwell-communications , Precision-cataract-surgery-platform

Alcon Inc. Corporate: Alcon's SMARTCataract Demonstrates Enhanced Efficiency and Time Savings for Cataract Surgeries

Data presented at ASCRS 2022 highlights substantial time efficiencies for cataract surgery planned with SMARTCataract-based on real-world cases1 SMARTCataract capabilities now upgraded with

Sweden , Geneva , Genè , Switzerland , United-states , Utah , American , Swedish , Acta-ophthalmol-scand , Zachary-zavodni , Brian-oneal , Clin-ophthalmol